Effects of Sugammadex and Conventional Reversal on Lung Function in Laparoscopic Abdominal Surgery

Launched by RHENDRA HARDY MOHAMAD ZAINI · Jan 6, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how two different medications—Sugammadex and a traditional reversal drug called neostigmine—affect lung function after laparoscopic abdominal surgery, which is a minimally invasive procedure. The researchers want to find out if there are any differences in lung function tests and the size of lung areas that may have collapsed (called atelectasis) between the two groups of patients. They will also see if the type of medication affects how long patients stay in the hospital after surgery.

To participate, you need to be between 18 and 75 years old, have a diagnosis of appendicitis or gallstones, and be scheduled for laparoscopic surgery. Before the operation, you will have some lung tests and an ultrasound. After the surgery, depending on which medication you receive, you will have additional lung tests and ultrasounds to compare the effects. It’s important to know that if you have certain health conditions, such as unstable heart issues or chronic lung diseases, you may not be eligible for this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosed / suspected: appendicitis or cholelithiasis
• • Planned for laparoscopic operation under general anaesthesia
• • ASA I-III
• Exclusion Criteria:
• • 1. Unstable haemodynamic status
• • 2. Patient refusal to participate
• • 3. Altered mental status, cognitive function or mental disorder
• • 4. Admission to postoperative care unit (PACU) under mechanical ventilation
• • 5. Hypersensitivity to any of the drugs
• • 6. Acute or chronic lung diseases
• • 7. Neuromuscular disorders
• • 8. Myocardial infarction or coronary occlusion three months prior surgery
• • 9. Obesity BMI more or equal 30
• • 10. Intubation prior operating room arrival
• • 11. Pregnancy
• • 12. Converted to open surgery